R&D programs > Early Development Programs

Early Development Programs

As part of a spinoff from Vicuron Pharmaceuticals, Naicons acquired the following assets:

NAI-Acne

A semi-synthetic thiopeptide, produced by Planobispora rosea, highly selective against Propionibacterium acnes, including antibiotic-resistant strains. No activity against other skin flora. The compound targets elongation factor Tu in protein synthesis. It is being developed for the topical treatment of moderate-severe acne. Recently licensed to Cassiopea SpA, it has completed a phase II proof-of-concept clinical study.

NAI-107 (and related lantibiotics)

A family of related lantibiotics highly active and rapidly bactericidal against aerobic and anaerobic Gram-positive pathogens, including all antibiotic-resistant strains (e.g. MRSA and VRE). Efficacious in several experimental models of infection (septicemia, endocarditis, granuloma pouch), NAI-107, produced by Microbispora sp. 107891, has favorable pharmacological properties and a good safety profile. The compound inhibits cell wall synthesis by binding to lipid II. It is being developed for iv treatment of serious infections by Gram-positive bacteria. The compounds are available for licensing.

NAI-603

A semi-synthetic derivative of ramoplanin, produced by Actinoplanes sp. ATCC 33076, highly active against aerobic and anareobic Gram-positive pathogens, including all antibiotic-resistant strains (e.g. MRSA and VRE); rapidly bactericidal, well-tolerated and efficacious in experimental models of infection. It can be developed for iv or topical use for several indications. Favorable toxicological profile. The compound is available for licensing.

 
CONTACT US